JP2009536665A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536665A5
JP2009536665A5 JP2009510143A JP2009510143A JP2009536665A5 JP 2009536665 A5 JP2009536665 A5 JP 2009536665A5 JP 2009510143 A JP2009510143 A JP 2009510143A JP 2009510143 A JP2009510143 A JP 2009510143A JP 2009536665 A5 JP2009536665 A5 JP 2009536665A5
Authority
JP
Japan
Prior art keywords
dementia
salt
acid
salt according
weak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009510143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536665A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/068452 external-priority patent/WO2007134038A2/en
Publication of JP2009536665A publication Critical patent/JP2009536665A/ja
Publication of JP2009536665A5 publication Critical patent/JP2009536665A5/ja
Pending legal-status Critical Current

Links

JP2009510143A 2006-05-09 2007-05-08 （２ｓ）−（４ｅ）−ｎ−メチル−５−［３−（５−イソプロポキシピリジン）イル］−４−ペンテン−２−アミンの新規な塩形態 Pending JP2009536665A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74680806P 2006-05-09 2006-05-09
PCT/US2007/068452 WO2007134038A2 (en) 2006-05-09 2007-05-08 Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine

Publications (2)

Publication Number Publication Date
JP2009536665A JP2009536665A (ja) 2009-10-15
JP2009536665A5 true JP2009536665A5 (https=) 2010-06-17

Family

ID=38508791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009510143A Pending JP2009536665A (ja) 2006-05-09 2007-05-08 （２ｓ）−（４ｅ）−ｎ−メチル−５−［３−（５−イソプロポキシピリジン）イル］−４−ペンテン−２−アミンの新規な塩形態

Country Status (5)

Country Link
US (1) US8017785B2 (https=)
EP (4) EP2357174A1 (https=)
JP (1) JP2009536665A (https=)
CN (1) CN101528698A (https=)
WO (1) WO2007134038A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790757B2 (en) 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US8017785B2 (en) 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
WO2010080757A2 (en) * 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
US8703802B2 (en) 2010-05-20 2014-04-22 Targacept, Inc. Process for the preparation of aryl substituted olefinic amines

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192946A (en) * 1978-06-29 1980-03-11 Ciba-Geigy Corporation Process for producing 3-hydroxy-5-halopyridines
DE3148651A1 (de) * 1981-12-09 1983-07-21 Henkel Kgaa "haarfaerbemittel, enthaltend 5-halo-2,3-pyridindiole als kupplerkomponente"
US4582823A (en) * 1984-08-15 1986-04-15 Warner-Lambert Company Method for treating schizophrenia and medicaments therefor
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
IT1226727B (it) * 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
DE69016688T2 (de) * 1989-04-20 1995-10-05 Zambon Spa Dopamin-Medikament-Vorstufe.
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
WO1992012122A1 (en) 1990-12-27 1992-07-23 Abbott Laboratories N-protected aminoalkylaldehydes
DE69213559T2 (de) 1991-05-30 1997-02-27 Mitsui Toatsu Chemicals Tetravinylpyrazine-Verbindung, Verfahren zur Herstellung derselben und elektrolumineszentes Element und damit hergesteller nichtlinearer optischer Stoff
US5212188A (en) * 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
IT1274018B (it) * 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
DK0765320T3 (da) 1994-06-14 2001-11-26 Pfizer Benzimidazolonderivater med central dopaminerg aktivitet
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5616707A (en) * 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US20020052497A1 (en) * 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
JP4357001B2 (ja) * 1996-04-23 2009-11-04 ターガセプト，インコーポレイテッド 中枢神経系障害の予防及び治療のための医薬組成物
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5811442A (en) * 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
PT983249E (pt) 1997-05-08 2002-08-30 Pfizer Prod Inc Procesos e intermediarios para a preparacao de derivados de indazole substituidos
ATE491689T1 (de) 1997-10-27 2011-01-15 Neurosearch As Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6232316B1 (en) * 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
CA2677519A1 (en) 1998-06-16 1999-12-23 Targacept, Inc. Aryl substituted olefinic amines and their use as cholinergic receptors agonists
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6337351B1 (en) * 1998-10-22 2002-01-08 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
JP2003501416A (ja) 1999-06-07 2003-01-14 ターガセプト，インコーポレイテッド 医薬組成物およびその使用法
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
US6506769B2 (en) * 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
AU2001252350A1 (en) 2000-04-13 2001-10-30 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
US6743812B1 (en) * 2000-07-14 2004-06-01 Targacept, Inc. Pharmaceutical compositions and methods for use
US6432954B1 (en) * 2000-07-14 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
DE60222396T2 (de) 2001-03-29 2008-05-15 Eli Lilly And Co., Indianapolis N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
EP1463481A4 (en) 2001-12-14 2008-06-25 Targacept Inc METHOD AND COMPOSITIONS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM
AU2003226094A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
US20040044023A1 (en) * 2002-08-30 2004-03-04 Marc Cantillon Compositions and methods for treating or preventing memory impairment
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2005063296A2 (en) 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
US20050171088A1 (en) 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
WO2005105729A1 (en) 2004-02-13 2005-11-10 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
US7537590B2 (en) * 2004-07-30 2009-05-26 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
JP4148199B2 (ja) 2004-07-30 2008-09-10 松下電工株式会社 電気かみそり
JP5254616B2 (ja) * 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) * 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US8017785B2 (en) 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
US20080138416A1 (en) 2006-06-13 2008-06-12 Fmc Biopolymer As Method and systems for using biopolymer-based beads and hydrogels
US20080085888A1 (en) * 2006-09-15 2008-04-10 Breining Scott R Therapeutic Combinations
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
WO2008091592A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs

Similar Documents

Publication Publication Date Title
JP2009536665A5 (https=)
HRP20110570T1 (hr) Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora
FI3856341T3 (fi) (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä
US20210002295A1 (en) Small molecule degraders that recruit dcaf15
MX2010003346A (es) Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
CA2581025A1 (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
KR20150085053A (ko) 헤테로사이클릭 글루타미나아제 억제제
WO2010084160A1 (en) Phenylcyclopropylamine derivatives and their medical use
JP2004501969A5 (https=)
JP2009507909A5 (https=)
JP2008509187A5 (https=)
DE60108724D1 (de) Neue pyrazin-derivate oder salze davon, pharmazeutische zusammensetzungen, die die derivate oder deren salze enthalten und intermediate zu beider herstellung
MX2011007774A (es) Derivados de isoxazol-isoxazol e isoxazol-isotiazol.
RU2008148325A (ru) Полиморфные формы(2s)-(4е)-n-метил-5-(3-изопропоксипиридин)ил) 4-пентен-2амина для лечения расстройств центральной нервной системы
JP2007516193A5 (https=)
MX2011011477A (es) Derivados de isoxazol-piridazina.
JP2010505961A5 (https=)
MX2011011273A (es) Derivados de isoxazol-pirazol.
NO20034031L (no) Substituerte pyrazol- og tiazolpyrimidiner
FI3792254T3 (fi) Kiteisiä metyylitioniniumkloridihydraatteja
MX2009014001A (es) Derivados de isoxazol-imidazol.
JP2010520881A5 (https=)
JP2016512198A5 (https=)
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3